Irina Antonijevic appointed as chief medical officer at vasopharm
pharmafile | November 8, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |
vasopharma, a privately held biopharmaceutical company, announced on 8 November that it had appointed Irina Antonijevic as their chief medical officer. Irina Antonijevic will be tasked with advancing the clinical development of vasopharm’s lead ongoing program, VAS203. The VAS203 program is a treatment for traumatic brain injury, which is currently undergoing Phase III trials.
Irina Antonijevic brings more than 15 years of experience of global drug development in neuroscience to the role. Previous to joining vasopharma, she had worked at Genzyme, a subsidiary of Sanofi, for six years as director of clinical research.
Dr Andrew Clark, chairman of vasopharm’s Board, commented: “We are delighted that Dr Antonijevic will be joining the team at vasopharm. Not only will we benefit from her clinical capabilities in our ongoing pivotal study of VAS203 in TBI, but also from her extensive expertise in pre-clinical development as we examine the compound in additional indications. We see her commitment to vasopharm as a substantial endorsement of the potential of the programs underway at the company.”
Dr Irina Antonijevic, newly appointed Chief Medical Officer, added: “I am excited to join vasopharm’s dedicated team in addressing a major unmet medical need in Neurology. As a clinician scientist and drug developer, I was impressed by the team’s notable Phase II study design and the exceptional results achieved, which in turn have instructed the design of the ongoing confirmatory study. Furthermore, given its mechanism of action, VAS203 has great potential in a number of additional indications that we at vasopharm are passionate to explore.”
